SUMMA, Vincenzo
 Distribuzione geografica
Continente #
NA - Nord America 841
EU - Europa 322
AS - Asia 91
SA - Sud America 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 1257
Nazione #
US - Stati Uniti d'America 812
IT - Italia 219
CN - Cina 74
SE - Svezia 30
CA - Canada 29
FR - Francia 19
RU - Federazione Russa 14
DE - Germania 13
IE - Irlanda 9
IN - India 8
CH - Svizzera 7
GB - Regno Unito 5
IR - Iran 4
VN - Vietnam 4
CL - Cile 2
FI - Finlandia 2
UA - Ucraina 2
AM - Armenia 1
EU - Europa 1
NL - Olanda 1
SI - Slovenia 1
Totale 1257
Città #
Millbury 191
Chandler 174
Lawrence 138
Des Moines 93
Beijing 54
Wilmington 38
Ottawa 28
Napoli 16
Fairfield 15
Milan 13
Ashburn 10
Naples 10
Scafati 10
Arezzo 8
Augusta 7
Dearborn 7
Shenzhen 7
Redwood City 6
Gurgaon 5
Woodbridge 5
Braunschweig 4
Cava De' Tirreni 4
Dong Ket 4
Guangzhou 4
Hangzhou 4
Mondolfo 4
Portici 4
Rome 4
San Mateo 4
Wohlen 4
Ardabil 3
Boston 3
Fribourg 3
Leawood 3
Maniago 3
Nanjing 3
Nocera Superiore 3
Norwalk 3
Palermo 3
Redmond 3
Campobasso 2
Catanzaro 2
Coimbatore 2
Desio 2
Emeryville 2
Hayes 2
Helsinki 2
Kunming 2
Limatola 2
Nola 2
Oristano 2
Siena 2
Stockholm 2
Belmonte Mezzagno 1
Bonn 1
Brentford 1
Cambridge 1
Carinaro 1
Como 1
Delft 1
Enna 1
Frankfurt am Main 1
Freiburg im Breisgau 1
Grumo Nevano 1
Ischia 1
La Canada Flintridge 1
Latina 1
Lavello 1
Ljubljana 1
Messina 1
Mountain View 1
Ragusa 1
Rende 1
Riva 1
San Diego 1
Sant'oreste 1
Santa Maria a Vico 1
Sassano 1
Savona 1
Serrone 1
Sorrento 1
Toronto 1
Villejuif 1
West Lafayette 1
Totale 962
Nome #
Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities 41
5,6-Dihydroxypyrimidine Scaffold to Target HIV-1 Nucleocapsid Protein 37
Bicyclic pyrimidones as inhibitors of HIV-​integrase 31
Preparation of arylaminocarbonyl pyrrolo-​fused tricyclic sulfonamides as inhibitors of hepatitis B virus 29
6-Bromoindirubin-3′-oxime intercepts GSK3 signaling to promote and enhance skeletal muscle differentiation affecting miR-206 expression in mice 26
3-​Hydroxy-​4-​oxo-​4H-​pyrido[1,​2-​a]​pyrimidine-​2-​carboxylates-​A new class of HIV-​1 integrase inhibitors 23
Visible-light photocatalytic functionalization of isocyanides for the synthesis of secondary amides and ketene aminals 23
Antiviral agents for the treatment of hepatitis C virus infections 21
SARS-CoV-2 Entry Inhibitors: Small Molecules and Peptides Targeting Virus or Host Cells 21
Synthesis and SAR of 2-​(4,​5-​dihydroxy-​6-​carboxy-​pyrimidinyl) thiophenes as inhibitors of the Hepatitis C Virus NS5B Polymerase 20
4,​5-​Dihydroxypyrimidine Carboxamides and N-​Alkyl-​5-​hydroxypyrimidinone Carboxamides Are Potent, Selective HIV Integrase Inhibitors with Good Pharmacokinetic Profiles in Preclinical Species 20
Anti-inflammatory and immunomodulatory activity of Mangifera indica L. reveals the modulation of COX-2/mPGES-1 axis and Th17/Treg ratio 19
Preparation of dihydroxypyridinylpyrimidinecarboxamide derivatives for use as HIV-​1 nucleocapsid inhibitors 18
Combined Peptide and Small-Molecule Approach toward Nonacidic THIQ Inhibitors of the KEAP1/NRF2 Interaction 18
Natural Compounds Inhibit SARS-CoV-2 nsp13 Unwinding and ATPase Enzyme Activities 18
Thinned Nectarines, an Agro-Food Waste with Antidiabetic Potential: HPLC-HESI-MS/MS Phenolic Characterization and In Vitro Evaluation of Their Beneficial Activities 18
A Focus on Severe Acute Respiratory Syndrome ( SARS ) Coronavirus ( SARS‐CoVs ) 1 and 2 18
Allosteric inhibitors of hepatitis C virus NS5B polymerase thumb domain site II: Structure-​based design and synthesis of new templates 17
Dermatological and​/or cosmetic peptides for use in skin treatment 17
4-​Hydroxy-​5-​pyrrolinone-​3-​carboxamide HIV-​1 integrase inhibitors 16
Advances in the development of macrocyclic inhibitors of hepatitis C virus NS3-​4A protease 16
Application of an in Vitro Blood-Brain Barrier Model in the Selection of Experimental Drug Candidates for the Treatment of Huntington's Disease 16
Chasing a Breath of Fresh Air in Cystic Fibrosis (CF): Therapeutic Potential of Selective HDAC6 Inhibitors to Tackle Multiple Pathways in CF Pathophysiology 16
Improved Selective Class i HDAC and Novel Selective HDAC3 Inhibitors: Beyond Hydroxamic Acids and Benzamides 15
Aryl propargylic alcohols of high enantiomeric purity via lipase catalyzed resolutions 15
3-​Hydroxy-​4-​oxo-​4H-​pyrido[1,​2-​a]​pyrimidine-​2-​carboxylates; fast access to a heterocyclic scaffold for HIV-​1 integrase inhibitors 15
Hiv integrase inhibitors 15
Preparation of arylaminocarbonyl bicyclic sulfonamides as inhibitors of hepatitis B virus 15
Binding of a Noncovalent Inhibitor Exploiting the S' region Stabilizes the Hepatitis C virus NS3 Protease Conformation in the Absence of Cofactor 14
Chiral Azole Derivatives. 2. Synthesis of Enantiomerically Pure 1-​Alkylimidazoles 14
Heterocyclic compounds used in the treatment of kinetoplastid infection and their preparation 14
Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals 14
Preparation of heteroaryl heptanamide derivatives for use in the treatment of parasitic diseases 13
Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-​4A serine protease and the NS5B RNA-​dependent RNA polymerase 13
Compositions useful for the treatment of viral diseases 13
Design, Synthesis, and Biological Evaluation of New 1-(Aryl-1 H-pyrrolyl)(phenyl)methyl-1 H-imidazole Derivatives as Antiprotozoal Agents 12
From dihydroxypyrimidine carboxylic acids to carboxamide HIV integrase inhibitors 12
Structure-​Based Identification of HIV-​1 Nucleocapsid Protein Inhibitors Active against Wild-​Type and Drug-​Resistant HIV-​1 Strains 12
Preparation of macrocyclic quinoxaline peptide as HCV NS3 protease inhibitor 12
Identification of Inhibitors of SARS-CoV-2 3CL-Pro Enzymatic Activity Using a Small Molecule in Vitro Repurposing Screen 12
Preparation of quinazolines as antivirals for treatment of hepatitis C viral (HCV) infection 11
Preparation of 2-​aryldihydroxypyrimidine-​4-​carboxylic acids as hepatitis C viral polymerase inhibitors 11
Synthesis and Antiproliferative Activity of Nitric Oxide-Donor Largazole Prodrugs 11
VX-​950 vertex​/mitsubishi 10
Discovery of a selective series of inhibitors of Plasmodium falciparum HDACs 10
Macrocyclic compounds as antiviral agents 9
Preparation of macrocyclic peptides as HCV NS3 protease inhibitors 9
Heterocyclic compounds useful in the treatment of disorders that are ameliorated by inhibition of HDAC 9
Development of macrocyclic inhibitors of HCV NS3​/4A protease with cyclic constrained P2-​P4 linkers 9
Early metabolic response to acute myocardial ischaemia in patients undergoing elective coronary angioplasty 9
Discovery, synthesis and optimization of a new series of selective HIV integrase inhibitors leading to MK-​0518 currently in Phase III clinical trial for treatment of HIV​/AIDS 9
Preparation of hydroxyoxopyridopyrimidinecarboxamides as HIV integrase inhibitors 9
Preparation of tetrazolyl derivatives as HIV reverse transcriptase inhibitors 9
Hcv ns3 protease inhibitors 9
Preparation of N-​Ph dicarbamate derivatives as HIV reverse transcriptase inhibitors 9
Fused pyrimidinones as HIV integrase inhibitors and their preparation and use in the treatment of HIV infection 9
Preparation of N-​(4-​fluorobenzyl)​-​5-​hydroxy-​1-​methyl-​2-​(1-​methyl-​1-​[(5-​methyl-​1,​3,​4-​oxadiazol-​2-​yl)​carbonyl]​amino​ethyl)​-​6-​oxo-​1,​6-​dihydropyrimidine-​4-​carboxamide potassium salts as HIV integrase inhibitors 9
Nucleoside derivatives as inhibitors of viral polymerases 9
Preparation of oxalamido-​substituted tricyclic inhibitors of hepatitis B virus 9
Discovery of 4-((1-(1H-imidazol-2-yl)alkoxy)methyl)pyridines as a new class of Trypanosoma cruzi growth inhibitors 9
Easy access to α-ketoamides as SARS-CoV-2 and MERS Mpro inhibitors via the PADAM oxidation route 8
Preparation of macrocyclic peptides as HCV NS3 protease inhibitors 8
Preparation of peptide inhibitors of hepatitis C virus NS3 protease 8
Quantitative prediction of human clearance guiding the development of reltegravir (MK-​0518, isentress) and related HIV integrase inhibitors 8
Studies of metabolism and disposition of potent human immunodeficiency virus (HIV) integrase inhibitors using 19F-​NMR spectroscopy 8
The metabolism and disposition of a potent inhibitor of hepatitis C virus NS3​/4A protease 8
The synthesis of tetrahydropyridopyrimidones as a new scaffold for HIV-​1 integrase inhibitors 8
Preparation of nucleoside and nucleotide analogs as inhibitors of viral polymerases 8
Preparation of N-​substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase 8
Preparation of macrocyclic quinoline and naphthyridine peptides as HCV NS3 protease inhibitors useful in the treatment of hepatitis C infection 8
Preparation of arylaminocarbonyl bicyclic sulfonamides as inhibitors of hepatitis B virus 8
Identification of Isoform 2 Acid-Sensing Ion Channel Inhibitors as Tool Compounds for Target Validation Studies in CNS 7
Discovery and synthesis of HIV integrase inhibitors: Dihydroxypyrimidine-​4-​carboxamides as novel potent and selective agents 7
Preparation of tetrahydro-​4H-​pyrido[1,​2-​a]​pyrimidines and related compounds as HIV integrase inhibitors 7
Discovery and synthesis of HIV integrase inhibitors: Development of potent bioavailable N-​methyl pyrimidones 7
Preparation of dihydroxypyrimidine carboxamide inhibitors of HIV integrase 7
N-​(4-​Fluorobenzyl)​-​3-​hydroxy-​9,​9-​dimethyl-​4-​oxo-​6,​7,​8,​9-​tetrahydro-​4H-​pyrazino[1,​2-​a]​pyrimidine-​2-​carboxamides a novel class of potent HIV-​1 integrase inhibitors 7
Preparation of macrocyclic peptides as HCV NS3 protease inhibitors 7
Discovery of α,​γ-​Diketo Acids as Potent Selective and Reversible Inhibitors of Hepatitis C Virus NS5b RNA-​Dependent RNA Polymerase 7
Discovery of MK-​5172, a Macrocyclic Hepatitis C Virus NS3​/4a Protease Inhibitor 7
A useful methodology for the regioselective deprotection of 1,​3-​dibenzyluracils 7
Design and Synthesis of Bicyclic Pyrimidinones as Potent and Orally Bioavailable HIV-​1 Integrase Inhibitors 7
Largazole analogues as histone deacetylases inhibitors and anticancer agents: an overview on structure‐activity relationships 7
Researches on antiviral agents. 4. Studies on the chemistry of 6-​methyl-​2-​methoxy-​4-​O-​acyloxy and 6-​methyl-​2,​4-​di-​O-​acyloxypyrimidine derivatives as new acylation reagents and inhibitors of uracil DNA glycosylases 7
Preparation of peptidyl macrocyclic compounds as antiviral agents 7
Preparation of pyrimidinones as viral polymerase inhibitors 7
Diketoacid derivatives as inhibitors of viral polymerases 7
Optimization of 2-(1H-imidazo-2-yl)piperazines series of Trypanosoma brucei growth inhibitors as potential treatment for the second stage of HAT 7
Optimization of linear and cyclic peptide inhibitors of KEAP1-NRF2 protein-protein interaction 7
Application of a Rapid and Simple Technological Process to Increase Levels and Bioccessibility of Free Phenolic Compounds in Annurca Apple Nutraceutical Product 7
Beneficial Contribution to Glucose Homeostasis by an Agro-Food Waste Product Rich in Abscisic Acid: Results from a Randomized Controlled Trial 6
Preparation of peptidyl macrocyclic compounds as antiviral agents 6
Preparation of imidazole derivatives as inhibitors of hepatitis C virus polymerases 6
Preparation of peptidyl macrocyclic compounds as antiviral agents 6
Preparation of pyridopyrazinediones and pyrimidopyrazinediones as HIV integrase inhibitors 6
Identification and Biological Evaluation of a Series of 1H-​Benzo[de]​isoquinoline-​1,​3(2H)​-​diones as Hepatitis C Virus NS5B Polymerase Inhibitors 6
Synthesis of amides: an efficient and chemoselective method for the preparation of β-​lactam derivatives related to HLE inhibitors 6
Synthesis and antiviral properties of novel tetracyclic nucleoside inhibitors of hepatitis C NS5B polymerase 6
From dihydroxypyrimidine carboxylic acids to carboxamide HIV-​1 integrase inhibitors: SAR around the amide moiety 6
P2‐Quinazolinones and Bis‐Macrocycles as New Templates for Next‐Generation Hepatitis C Virus NS3/4a Protease Inhibitors: Discovery of MK‐2748 and MK‐6325 6
Totale 1198
Categoria #
all - tutte 3284
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3284

Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020240 0000 10612 2520 314546
2020/2021227 9220 1578 327 1753129
2021/2022567 84731 1618 036 222688311
2022/2023384 142391053 5649 350 0000
Totale 1418